J Endocr Soc 5(9):bvab118 Doggrell SA (2023) Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist, a step forward in the treatment of diabetes and obesity
A comprehensive program of nutritional and lifestyle counseling is critical to maximize overall efficacy and improve cost-effectiveness of GLP-1s for obesity Long-term Success of GLP-1s Hinges on More Than Just a Prescription A comprehensive program of nutritional and lifestyle counseling is critical to maximize overall efficacy and improve cost-effectiveness of GLP-1s for obesity GLP-1 (glucagon-like peptide-1) therapies can be powerful tools in managing obesity, with patients taking these medications seeing weight reductions of 518% in clinical trials, along with increased metabolism and benefits to their overall heart health
16 A subsequent three-month lead-in period was applied before evaluating cancer incidence
That is why each titration phase is 4 weeks long: it gives the dose time to reach a steady level before the next step up
NICE guidance provides clear recommendations for GLP-1 use, which focus exclusively on glycaemic control in type 2 diabetes (NG28) and weight management in obesity (TA875 for semaglutide, TA664 for liraglutide)
Your medical provider will determine the appropriate patch strength for you based on your medical history and treatment goals, which may differ from an injection dosage
